Table 2.

Reported time to clean skin lesion by half and treatment persistence time from the surveyed patients with msPsO and dermatologists

	Patients with msPsO		Dermatologists
	N	Mean ± SD/%	N	Mean ± SD/%
Time to clean skin lesion by half (weeks)
Oral treatment
Acitretin	85	5.8 ± 3.5	47	6.5 ± 3.2
Methotrexate	48	6.9 ± 5.4	46	6.1 ± 2.6
Cyclosporine	5	7.2 ± 3.3	44	5.6 ± 2.5
Apremilast	2	6.0 ± 2.8	26	5.8 ± 2.9
Biologic treatment
Infliximab	7	5.9 ± 6.4	35	4.5 ± 1.6
Adalimumab	39	6.5 ± 6.4	49	5.2 ± 2.8
Etanercept	15	6.5 ± 4.1	42	6.1 ± 2.9
Secukinumab	36	4.0 ± 2.3	50	2.9 ± 1.5
Ixekizumab	19	3.4 ± 2.5	50	2.6 ± 1.5
Ustekinumab	9	3.9 ± 1.8	47	5.1 ± 3.0
Guselkumab	0	–	43	4.1 ± 2.2
Treatment persistence time (months)
Oral treatment
Acitretin	126	6.2 ± 5.8	47	4.7 ± 1.9
Methotrexate	73	4.9 ± 4.6	46	4.6 ± 1.9
Cyclosporine	15	5.5 ± 7.6	44	4.1 ± 2.0
Apremilast	5	2.7 ± 2.3	22	5.7 ± 2.6
Biologics
Infliximab	8	17.0 ± 9.5	36	11.7 ± 5.8
Adalimumab	51	12.1 ± 10.0	48	11.7 ± 7.8
Etanercept	18	14.4 ± 10.0	41	9.7 ± 5.6
Secukinumab	43	10.5 ± 6.8	50	15.7 ± 9.1
Ixekizumab	25	9.7 ± 8.3	47	15.0 ± 9.0
Ustekinumab	15	9.5 ± 8.4	46	13.7 ± 6.8
Guselkumab	0	–	39	12.2 ± 6.6

msPsO moderate-to-severe psoriasis, SD standard deviation